2 weeks Ago By ABMN Staff
Kathmere Capital Management LLC acquired a new position in shares of Thermo Fisher Scientific Inc. ( NYSE:TMO – Free Report ) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 679 shares of the medical research company’s stock, valued at approximately $375,000.
A number of other institutional investors and hedge funds have also made changes to their positions in the company. Beaumont Financial Advisors LLC increased its holdings in shares of Thermo Fisher Scientific by 0.8% during the 1st quarter.
Beaumont Financial Advisors LLC now owns 2,199 shares of the medical research company’s stock worth $1,278,000 after buying an additional 17 shares during the last quarter. Cedar Wealth Management LLC increased its holdings in shares of Thermo Fisher Scientific by 14.5% during the 1st quarter.
Cedar Wealth Management LLC now owns 134 shares of the medical research company’s stock worth $78,000 after buying an additional 17 shares during the last quarter. Lafayette Investments Inc. increased its holdings in shares of Thermo Fisher Scientific by 2.
1% during the 2nd quarter. Lafayette Investments Inc. now owns 830 shares of the medical research company’s stock worth $459,000 after buying an additional 17 shares during the last quarter.
Patrick M Sweeney & Associates Inc. increased its holdings in Thermo Fisher Scientific by 1.8% in the 2nd quarter.
Patrick M Sweeney & Associates Inc. now owns 1,031 shares of the medical research company’s stock valued at $570,000 after purchasing an additional 18 shares in the last quarter. Finally, Drive Wealth Management LLC increased its holdings in Thermo Fisher Scientific by 0.
9% in the 2nd quarter. Drive Wealth Management LLC now owns 2,123 shares of the medical research company’s stock valued at $1,175,000 after purchasing an additional 18 shares in the last quarter. 89.
23% of the stock is currently owned by institutional investors and hedge funds. Insiders Place Their Bets In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $600.
85, for a total value of $180,255.00. Following the sale, the executive vice president now owns 17,887 shares in the company, valued at $10,747,403.
95. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website . In other Thermo Fisher Scientific news, CEO Marc N.
Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total value of $6,172,100.
00. Following the sale, the chief executive officer now owns 123,816 shares in the company, valued at $76,420,473.36.
The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website . Also, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $600.
85, for a total transaction of $180,255.00. Following the transaction, the executive vice president now owns 17,887 shares in the company, valued at approximately $10,747,403.
95. The disclosure for this sale can be found here . Insiders have sold 23,084 shares of company stock valued at $14,094,292 over the last quarter.
Insiders own 0.34% of the company’s stock. Thermo Fisher Scientific Stock Performance Thermo Fisher Scientific ( NYSE:TMO – Get Free Report ) last issued its earnings results on Wednesday, July 24th.
The medical research company reported $5.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.13 by $0.
24. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.
22%. The firm had revenue of $10.54 billion for the quarter, compared to analysts’ expectations of $10.
50 billion. During the same quarter last year, the company posted $5.15 earnings per share.
Thermo Fisher Scientific’s revenue was down 1.4% on a year-over-year basis. Equities analysts anticipate that Thermo Fisher Scientific Inc.
will post 21.72 earnings per share for the current fiscal year. Thermo Fisher Scientific Announces Dividend The firm also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th.
Shareholders of record on Friday, September 13th will be issued a $0.39 dividend. The ex-dividend date of this dividend is Friday, September 13th.
This represents a $1.56 dividend on an annualized basis and a yield of 0.25%.
Thermo Fisher Scientific’s dividend payout ratio is currently 10.01%. Wall Street Analysts Forecast Growth Several brokerages recently issued reports on TMO.
Robert W. Baird increased their price target on Thermo Fisher Scientific from $620.00 to $632.
00 and gave the company an “outperform” rating in a report on Thursday, July 25th. Raymond James increased their price target on Thermo Fisher Scientific from $650.00 to $660.
00 and gave the company an “outperform” rating in a report on Thursday, July 25th. Barclays lowered their price target on Thermo Fisher Scientific from $615.00 to $600.
00 and set an “equal weight” rating for the company in a report on Friday, June 28th. Evercore ISI decreased their price objective on shares of Thermo Fisher Scientific from $615.00 to $600.
00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd. Finally, Wells Fargo & Company started coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $670.
00 price objective for the company. Four research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.
com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $650.41. Check Out Our Latest Analysis on TMO Thermo Fisher Scientific Profile ( Free Report ) Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally.
The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Featured Stories Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc.
( NYSE:TMO – Free Report ). Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter .
.
